z-logo
open-access-imgOpen Access
Modern possibilities of hypertension drug therapy. Candesartan and its place in the therapy
Author(s) -
О. Л. Барбараш,
В В Кашталап
Publication year - 2013
Publication title -
sistemnye gipertenzii
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/sg28988
Subject(s) - candesartan , medicine , blood pressure , antihypertensive drug , blockade , pharmacotherapy , angiotensin receptor , drug , pharmacology , angiotensin ii , renin–angiotensin system , cardiology , receptor
Arterial hypertension (AH) remains the one of the major cardiovascular diseases in the adult population and a major factor in cardiovascular and cerebrovascular morbidity and mortality. Drug therapy of hypertension leads to a reduction of cardiovascular risk by affecting blood pressure. Renin-angiotensin-aldosterone system (RAAS) plays a key role in the formation of hypertension, as the drug blockade of its components can significantly improve the prognosis of patients. The principal means of blocking the RAAS are angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists II (ARA II, sartans). Both classes of drugs have shown their high antihypertensive efficacy, with the ARA II having almost perfect portability. Recently, however, sartans’independent rolein the treatment of hypertension has been questioned. Date overview of the evidence base of sartans with a focus on modern antihypertensive drug called candesartan cilexetil was the following work’s objective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here